Adverse Event Profile of Spiramycin: A Comprehensive Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database

Fuente: Zenodo

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	Nehad Jaser Ahmed
Format:	Recurso digital
Veröffentlicht:	Zenodo 2026
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Descriptive Analysis of Amiloride Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS): A Retrospective Pharmacovigilance Study
von: Nehad Jaser Ahmed
Veröffentlicht: (2026)

Descriptive Analysis of Alteplase Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS): A Retrospective Pharmacovigilance Study
von: Nehad Jaser Ahmed
Veröffentlicht: (2026)

Descriptive Analysis of Ranolazine Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
von: Nehad Jaser Ahmed
Veröffentlicht: (2026)

Descriptive Analysis of DALTEPARIN Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
von: Nehad Jaser Ahmed
Veröffentlicht: (2026)

DOFETILIDE Descriptive Analysis of Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
von: Nehad Jaser Ahmed
Veröffentlicht: (2026)

Prazosin Adverse Events: A Descriptive Analysis of the FDA Adverse Event Reporting System (FAERS)
von: Nehad Jaser Ahmed
Veröffentlicht: (2026)

Labetalol: A Descriptive Analysis of Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
von: Nehad Jaser Ahmed
Veröffentlicht: (2026)

HYDROCHLOROTHIAZIDE ADVERSE EVENTS A Descriptive Analysis of Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
von: Nehad Jaser Ahmed
Veröffentlicht: (2026)

Pharmacovigilance Analysis of Drug-Induced Rhabdomyolysis Based on the FDA Adverse Event Reporting System (FAERS)
von: Liang, Enpu
Veröffentlicht: (2025)

A Real‐World Pharmacovigilance Study of Fruquintinib Based on the FDA Adverse Event Reporting System ( FAERS ) Database
von: Yajing Xu, et al.
Veröffentlicht: (2025)

Indications and Adverse Events of Toradol: Based on FDA Adverse Event Reporting System (FAERS)
von: Jiaqi Guo, et al.
Veröffentlicht: (2026)

Adverse Events Associated With Dabrafenib, Trametinib, and Their Combination Therapy: A Disproportionality Analysis of the FDA Adverse Event Reporting System ( FAERS ) Database
von: Zhenpo Zhang, et al.
Veröffentlicht: (2025)

Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database
von: Jiayu Yuan, et al.
Veröffentlicht: (2024)

Analysis of Predictors of Adverse Events and Mortality Risk Associated With IL‐6 Inhibitors: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database
von: Meilin Fang, et al.
Veröffentlicht: (2025)

Neoplasm Adverse Events Associated With Anti‐Type 2 Biologics: An FAERS Database Pharmacovigilance Analysis Study
von: Wen Lyu, et al.
Veröffentlicht: (2026)

Evaluating the Evolving Real‐World Adverse Events of GLP ‐ 1RAs Using FDA Adverse Event Reporting System ( FAERS )
von: David Stone, et al.
Veröffentlicht: (2026)

A Real‐World Pharmacovigilance Study of FDA Adverse Event Reporting System Events for Obeticholic Acid
von: Le Hai, et al.
Veröffentlicht: (2025)

Vismodegib and Sonidegib Are Associated With an Elevated Reporting Odds of Squamous Cell Carcinoma; a Comparative Pharmacovigilance Study of the FDA Adverse Events Reporting System ( FAERS )
von: Patrick Jedlowski, et al.
Veröffentlicht: (2025)

Low‐Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System ( FAERS ) With a Focus on Pericardial Effusions
von: Aditya K. Gupta, et al.
Veröffentlicht: (2024)

Drug‐Induced Acute Pancreatitis: A Real‐World Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database
von: Dongxuan Li, et al.
Veröffentlicht: (2024)

Comprehensive safety assessment of ribociclib: A real‐world analysis using the FDA Adverse Event Reporting System (FAERS) database
von: Lan Luo, et al.
Veröffentlicht: (2025)

A Real‐World Study on Adverse Reactions of Belimumab Based on the FDA Adverse Event Reporting System Database
von: Le Hai, et al.
Veröffentlicht: (2024)

The Cardiovascular Safety of Antiparkinsonian Drugs—Analysis of Signals in the FDA Adverse Event Report System Database
von: Xin Mu, et al.
Veröffentlicht: (2026)

ADHD medications and drug withdrawal: A pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database
von: Takumi Ebina, et al.
Veröffentlicht: (2026)

Post‐Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System
von: Tung S. Tran, et al.
Veröffentlicht: (2025)

A Pharmacovigilance Study of Immune Checkpoint Inhibitor‐Associated Cholangitis: Insights From the FDA Adverse Event Reporting System
von: Haowen Tan, et al.
Veröffentlicht: (2025)

Hepatobiliary Adverse Events Linked to Immune Checkpoint Inhibitors: A Real‐World Pharmacovigilance Analysis Using FAERS Data
von: Yuzhu Chen, et al.
Veröffentlicht: (2025)

Safety analysis of gepants for migraine treatment: A pharmacovigilance study using the FDA Adverse Event Reporting System ( FAERS ) database
von: Hui Chen, et al.
Veröffentlicht: (2026)

Aioli: Standardising Drugs in the FDA Adverse Event Reporting System ( FAERS ) to RxNorm and Anatomical Therapeutic Chemical ( ATC ) Codes
von: Rowan E. Parry, et al.
Veröffentlicht: (2025)

Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System
von: Shaimaa Elshafie, et al.
Veröffentlicht: (2024)

Bridging FDA Adverse Event Reporting System ( FAERS ) and Clinical Practice: Comprehensive Characterization of Immune Checkpoint Inhibitors Toxicities in Geriatric Lung Cancer Patients
von: Yumeng Tian, et al.
Veröffentlicht: (2026)

A Real‐World Study of CAR‐T Hematological Adverse Events Based on FAERS Database
von: Xiaoyue Gao, et al.
Veröffentlicht: (2025)

Comparative Post‐Marketing Surveillance of Memantine and Cholinesterase Inhibitors: Cardiovascular Adverse Events With a Focus on Sex Differences Using the FDA Adverse Event Reporting System Database
von: Zinnet Şevval Aksoyalp, et al.
Veröffentlicht: (2024)

Drug‐Induced Liver Injury Associated With Moxifloxacin: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and a Real‐World Retrospective Study
von: Yanqing Song, et al.
Veröffentlicht: (2025)

FDA Adverse Event Reporting System Essentials: A Reflection on Study Conception
von: Emanuel Raschi, et al.
Veröffentlicht: (2025)

Postmarketing Safety Surveillance of Topiramate: A Signal Detection and Analysis Study Based on the FDA Adverse Event Reporting System Database
von: Kai Lin, et al.
Veröffentlicht: (2024)

Drug‐Related Hypertension: A Disproportionality Analysis Leveraging the FDA Adverse Event Reporting System
von: Hao Zhu, et al.
Veröffentlicht: (2025)

A Real‐World Disproportionality Analysis of Histamine H2‐Receptors Antagonists (Famotidine): A Pharmacovigilance Study Based on Spontaneous Reports in the FDA Adverse Event Reporting System
von: Dongdong Zhang, et al.
Veröffentlicht: (2025)

Lichen Planus Pemphigoides as an Adverse Reaction to Medication Use: A Retrospective Analysis of Commonly Implicated Medication Triggers Using the FDA Adverse Events Reporting Database
von: Gaurav N. Pathak, et al.
Veröffentlicht: (2025)

Pharmacovigilance of obeticholic acid: An analysis of the Food and Drug Administration Adverse Event Reporting System database
von: Qining He, et al.
Veröffentlicht: (2025)